These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25850019)

  • 61. Innovative vaccine delivery strategies in response to a cholera outbreak in the challenging context of Lake Chilwa. A rapid qualitative assessment.
    Heyerdahl LW; Ngwira B; Demolis R; Nyirenda G; Mwesawina M; Rafael F; Cavailler P; Bernard Le Gargasson J; Mengel MA; Gessner BD; Guillermet E
    Vaccine; 2018 Oct; 36(44):6491-6496. PubMed ID: 29126808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
    Im J; Islam MT; Ahmmed F; Kim DR; Chon Y; Zaman K; Khan AI; Ali M; Marks F; Qadri F; Clemens JD
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007179. PubMed ID: 30870416
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of oral cholera vaccine as a vaccine probe to define the geographical dimensions of person-to-person transmission of cholera.
    Ali M; Kim DR; Kanungo S; Sur D; Manna B; Digilio L; Dutta S; Marks F; Bhattacharya SK; Clemens J
    Int J Infect Dis; 2018 Jan; 66():90-95. PubMed ID: 29174695
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vaxchora: A Single-Dose Oral Cholera Vaccine.
    Cabrera A; Lepage JE; Sullivan KM; Seed SM
    Ann Pharmacother; 2017 Jul; 51(7):584-589. PubMed ID: 28622736
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.
    Richie EE; Punjabi NH; Sidharta YY; Peetosutan KK; Sukandar MM; Wasserman SS; Lesmana MM; Wangsasaputra FF; Pandam SS; Levine MM; O'Hanley PP; Cryz SJ; Simanjuntak CH
    Vaccine; 2000 May; 18(22):2399-410. PubMed ID: 10738097
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Preliminary report; Philippines Cholera Committee.
    Philippines Cholera Committee
    Bull World Health Organ; 1965; 32(5):603-25. PubMed ID: 5294176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.
    Parker LA; Rumunu J; Jamet C; Kenyi Y; Lino RL; Wamala JF; Mpairwe AM; Muller V; Llosa AE; Uzzeni F; Luquero FJ; Ciglenecki I; Azman AS
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005652. PubMed ID: 28594891
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario.
    Smalley HK; Keskinocak P; Swann J; Hinman A
    Vaccine; 2015 Nov; 33(46):6218-23. PubMed ID: 26458806
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
    Schaetti C; Weiss MG; Ali SM; Chaignat CL; Khatib AM; Reyburn R; Duintjer Tebbens RJ; Hutubessy R
    PLoS Negl Trop Dis; 2012; 6(10):e1844. PubMed ID: 23056660
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique.
    Cavailler P; Lucas M; Perroud V; McChesney M; Ampuero S; Guérin PJ; Legros D; Nierle T; Mahoudeau C; Lab B; Kahozi P; Deen JL; von Seidlein L; Wang XY; Puri M; Ali M; Clemens JD; Songane F; Baptista A; Ismael F; Barreto A; Chaignat CL
    Vaccine; 2006 May; 24(22):4890-5. PubMed ID: 16298025
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015.
    Lam E; Al-Tamimi W; Russell SP; Butt MO; Blanton C; Musani AS; Date K
    Emerg Infect Dis; 2017 Jan; 23(1):38-45. PubMed ID: 27983502
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A controlled field trial of the effectiveness of various doses of cholera El Tor vaccine in the Philippines.
    Philippines Cholera Committee
    Bull World Health Organ; 1968; 38(6):917-23. PubMed ID: 5303665
    [TBL] [Abstract][Full Text] [Related]  

  • 74. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
    Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Dialo AA; Itama C; Serafini M; Legros D; Grais RF
    PLoS Negl Trop Dis; 2013; 7(10):e2465. PubMed ID: 24147164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam.
    Vu DT; Hossain MM; Nguyen DS; Nguyen TH; Rao MR; Do GC; Naficy A; Nguyen TK; Acosta CJ; Deen JL; Clemens JD; Dang DT
    J Health Popul Nutr; 2003 Dec; 21(4):304-8. PubMed ID: 15043004
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014.
    Azman AS; Rumunu J; Abubakar A; West H; Ciglenecki I; Helderman T; Wamala JF; Vázquez Ode L; Perea W; Sack DA; Legros D; Martin S; Lessler J; Luquero FJ
    Emerg Infect Dis; 2016 Jun; 22(6):1067-70. PubMed ID: 27192187
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Socioeconomic drivers of vaccine uptake: An analysis of the data of a geographically defined cluster randomized cholera vaccine trial in Bangladesh.
    Saha A; Hayen A; Ali M; Rosewell A; MacIntyre CR; Clemens JD; Qadri F
    Vaccine; 2018 Jul; 36(31):4742-4749. PubMed ID: 29752024
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Chowdhury F; Akter A; Bhuiyan TR; Tauheed I; Teshome S; Sil A; Park JY; Chon Y; Ferdous J; Basher SR; Ahmed F; Karim M; Ahasan MM; Mia MR; Masud MMI; Khan AW; Billah M; Nahar Z; Khan I; Ross AG; Kim DR; Ashik MMR; Digilio L; Lynch J; Excler JL; Clemens JD; Qadri F
    Vaccine; 2022 Jan; 40(4):640-649. PubMed ID: 34969541
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Household and Individual Risk Factors for Cholera among Cholera Vaccine Recipients in Rural Haiti.
    Matias WR; Teng JE; Hilaire IJ; Harris JB; Franke MF; Ivers LC
    Am J Trop Med Hyg; 2017 Aug; 97(2):436-442. PubMed ID: 28722575
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.